Cargando…
Impact of the COVID‐19 pandemic on care disruptions, outcomes, and costs in patients receiving pulmonary arterial hypertension‐specific therapy in the United States of America: An observational study
Regular expert follow‐up, risk assessment, and early therapeutic intervention minimize worsening of pulmonary arterial hypertension (PAH). COVID‐19 lockdown measures were challenging for chronic disease management. This retrospective, longitudinal analysis used US claims data (January 12, 2016 to Se...
Autores principales: | George, Marjorie Patricia, Germack, Hayley D., Goyal, Amit, Ward, Charlotte, Studer, Sean, Panjabi, Sumeet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493079/ https://www.ncbi.nlm.nih.gov/pubmed/37701141 http://dx.doi.org/10.1002/pul2.12283 |
Ejemplares similares
-
Real-World Treatment Patterns Among Patients with Connective Tissue Disorder-Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis
por: Sargent, Therese, et al.
Publicado: (2023) -
Economic burden of illness among patients with pulmonary arterial hypertension (PAH) associated with connective tissue disorders (CTD)
por: Tsang, Yuen, et al.
Publicado: (2023) -
The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States
por: Ogbomo, Adesuwa, et al.
Publicado: (2022) -
Cost of peripheral neuropathy in patients receiving treatment for
multiple myeloma: a US administrative claims analysis
por: Song, Xue, et al.
Publicado: (2019) -
Predicting Risk of 1-Year Hospitalization Among Patients with Pulmonary Arterial Hypertension
por: Zhang, Chang, et al.
Publicado: (2023)